🇺🇸 FDA
Patent

US 10202602

Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups

granted A61KA61K31/496A61K31/5377

Quick answer

US patent 10202602 (Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups) held by Sarepta Therapeutics, Inc. expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue Feb 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K31/496, A61K31/5377, A61P, A61P13/12